Understanding the underlying mechanisms may provide a theoretical basis for the clinical therapy of HCC and RCCRecent approaches for gene therapy targeting lncRNAs to suppress ABC transporters show promise in reversing HCC and RCC chemoresistance [105]. The gene discussed is ABCG2; the disease is hepatocellular carcinoma.